This phase II cohort study examined the cardiac safety of paclitaxel and trastuzumab in patients with node-negative, ERBB2-positive breast cancer and found that the cardiac toxic effects were low, suggesting that left ventricular ejection fraction monitoring could be simplified for many patients.
This genetic database analysis of stage II colon cancer samples finds that certain gene signature sets may serve as prognostic predictors and facilitate the identification of patients who could gain survival benefit from fluorouracil adjuvant chemotherapy.
This study uses rabbit monoclonal antibodies to demonstrate PD-L1 protein expression in human non–small-cell lung cancer biopsy specimens and found heterogeneity within tumors and interassay discordance.
This exploratory analysis of data from the N9831 trial evaluated the association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer treated with chemotherapy or chemotherapy plus trastuzumab.
This systematic review and meta-analysis provides evidence suggesting that gonadotropin-releasing hormone agonists given concurrently with chemotherapy to premenopausal patients undergoing treatment for early-stage breast cancer is associated with prevention of early menopause.
This decision analysis study investigated the optimal duration of time-limited trials of intensive care among critically ill patients with cancer.
This study of a SEER-Medicare linked database found that black men treated with radical prostatectomy for prostate cancer are more likely to experience adverse events and incur higher costs compared with non-Hispanic white men, but this does not translate into a difference in mortality.
This study of SEER data on women with stage I to III breast cancer undergoing mastectomy investigated whether changes in National Comprehensive Cancer Network guidelines have increased use of postmastectomy radiation therapy and affected receipt of breast reconstruction.
This large case series found that germline variants were common in individuals with advanced cancer who underwent tumor-normal genetic sequencing, which may prove useful in revealing otherwise unsuspected syndromic associations.
This cohort study uses National Inpatient Sample database data to compare the incidence of procedure-related adverse events with endoscopic vs percutaneous drainage of malignant biliary tract obstruction..
This report details benefit-risk assessment and rationale for expedited approval by the US Food and Drug Administration of nivolumab, a new therapy for metastatic squamous non–small-cell lung cancer.
Academic scientists and scientists employed by manufacturers of erythropoiesis-stimulating agents report opposite findings in studies of the existence of functional erythropoietin receptors on cancer cells.
This retrospective review finds that positron emission tomography coupled with computed tomography has a high false-positive rate for sentinel lymph node mapping.
This survey finds that lower patient income level is associated with lower likelihood of clinical trial participation.
This investigation of recent news coverage of cancer research found that although most new cancer drugs offer only modest benefits, they are often described in the news media with superlatives, such as “revolutionary” and “game changer,” that may be unwarranted.
This review summarizes current management of hairy cell leukemia and novel therapies currently under investigation in clinical trials or already in use.
This diagnostic challenge describes a patient who presented with progressive inguinal lymphadenopathy and a leukocytosis of 144 000/µL with 97% lymphocytes who eventually achieved complete remission but experienced disease recurrence 6 months later.
This Viewpoint suggests ways to add efficiency to cancer research, including decreased costs as an explicit goal of clinical trials, data sharing, and enhanced accountability for cancer research dollars.
This Viewpoint highlights the role of next-generation sequencing in the rapid emergence of new cancer therapies as well as the challenges of safely regulating these therapies without unnecessarily delaying their implementation.
This Viewpoint summarizes the role of PD-1 and PD-L1 in antibody therapies to treat certain cancers and calls for a harmonization in developing PD-1/PD-L1 inhibitors and assays to standardize testing to further this cancer therapy.
This Viewpoint describes why the 21st Century Cures Act will be a milestone in US legislation, for drug development, medical innovation and research, and benefits to patients.
This commentary reviews the conclusions of a study concerning number of cutaneous squamous cell carcinomas (CSCCs) and patient outcomes and reiterates the importance of examinations for patients with multiple CSCCs.
Create a personal account or sign in to: